BioWorld

Oct. 12, 2005

View Archived Issues

DNA Beats Consensus With Avastin, Herceptin Growth

Once again beating consensus estimates, Genentech Inc. reported a strong third quarter driven by better-than-expected sales of Avastin and Herceptin, two products that are increasingly being prescribed off-label. (BioWorld Today) Read More

CepTor Adding $20M To Test Myodur In Muscular Dystrophy

Read More

Antigenics Reports Positive Data From Oncophage Trial

Read More

VIRxSYS Series F Raises $31M To Boost HIV Drug

Read More

Praecis Continues Cost-Cutting Efforts, Sells Research Facility

Read More

Other News To Note

Read More

Appointments And Advancements

Read More